CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Active
Keytruda pembrolizumab Non-small cell lung cancer (NSCLC) Received
Keytruda pembrolizumab Unresectable or metastatic MSI-H or dMMR solid tumors Received
Keytruda pembrolizumab Biliary tract carcinoma Active
Keytruda pembrolizumab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
Keytruda pembrolizumab Gastrointestinal Cancer Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda pembrolizumab Primary mediastinal B-cell lymphoma Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda Pembrolizumab head and neck squamous cell carcinoma (HNSCC) Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Esophageal carcinoma, gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Last Updated : July 28, 2024